fda compounding semaglutide warning september 2025 Article: Brazilian Clinics and the False Equivalence of Compounded GLP-1 Drugs: ANVISA should follow Compounded "semaglutide" is not FDA-approved

TMA's action in pathological conditions

The peptide is a man-made variant of the thymosin beta-4 (T4) peptide found naturally within the cells of the thymus organ, and encoded by the TMSB4X gene

The mechanistic hypothesis: Semaglutide activates GLP-1R, appetite suppression, glycemic control Cagrilintide activates amylin receptors, appetite suppression via the area postrema, slowing of gastric evacuation Two independent mechanisms of appetite suppression a supra-additive effect In Phase 1b and Phase 2 trials the combination showed a stronger effect than either component alone : Semaglutide alone: 14.9 % (STEP-1) Cagrilintide alone (Phase 2): 10.8 % CagriSema combination (Phase 2): 15.6 % CagriSema Phase 3 (REDEFINE 1): 25.3 % CagriSema thus becomes the largest body-weight signal reported in the published incretin literature to date , stronger than Tirzepatide (22.5 % in SURMOUNT-1) and comparable to Retatrutide

Size: 1 mL

It is critical for maintaining DNA stability and synthesis (Wang et al., 2018) and supports processes such as apoptosis and autophagy, crucial for removing damaged cells and maintaining cellular health (Hofer et al., 2021)